Question 1

What is Nektar Therapeutics's restructuring costs and asset impairment charges?

Accepted Answer

Nektar Therapeutics (NKTR) reported restructuring costs and asset impairment charges of $796K in Q1 2026.

Question 2

How has Nektar Therapeutics's restructuring costs and asset impairment charges changed year-over-year?

Accepted Answer

Nektar Therapeutics's restructuring costs and asset impairment charges increased by 371.0% year-over-year, from $169K to $796K.

Question 3

What does restructuring costs and asset impairment charges mean?

Accepted Answer

This metric represents non-recurring expenses incurred from organizational restructuring initiatives and the write-down of asset values. It reflects management's efforts to streamline operations or adjust to changing business conditions by disposing of assets or reducing workforce. Investors monitor this to distinguish between core operational performance and one-time charges that impact profitability.

Line item	Three Months Ended March 31,	Three Months Ended March 31,
Operating costs and expenses:
Research and development (including $1,708 and $208 for the three months ended March 31, 2026 and 2025, respectively, from a related party)	35,680	30,480
General and administrative	13,439	24,346
Restructuring and impairment	796	169
Total operating costs and expenses	49,915	54,995
Loss from operations	(39,054)	(44,535)
Non-operating income (expense):
Non-cash interest expense on liabilities related to the sales of future royalties	(7,942)	(4,974)

Restructuring Costs And Asset Impairment Charges at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Nektar Therapeutics's restructuring costs and asset impairment charges.

Nektar Therapeutics NKTR Restructuring Costs And Asset Impairment Charges